SymBio Pharmaceuticals Limited 

SymBio Pharmaceuticals Limited, a Japanese company founded in 2005 and headquartered in Tokyo, specializes in the research, development, manufacturing, and commercialization of pharmaceutical products primarily for oncology and hematology. A significant part of its portfolio is the anticancer agent Treakisym SyB L-0501. Marketed as TREAKISYM, this drug is utilized in treating non-Hodgkin's lymphoma, multiple myeloma, and chronic lymphocytic leukemia. Furthermore, it is currently in Phase III clinical trials for the treatment of relapsed/refractory diffuse large B-cell lymphoma. SymBio is also advancing the development of SyB L-1701, available as a ready-to-dilute formulation, and SyB L-1702, a rapid infusion liquid formulation. Moreover, the company's pipeline includes SyB L-1101, an intravenous drug undergoing Phase III trials for higher-risk myelodysplastic syndromes (HR-MDS). Concurrently, SyB C-1101, an oral formulation, is in Phase II/III clinical trials for HR-MDS when administered in combination with Azacitidine. Additionally, SymBio is developing SyB V-1901, an antiviral medication targeting infectious diseases.